PNTG Quote, Financials, Valuation and Earnings

Ensign Group has a net margin of 3.43% compared to Pennant Group's net margin of 7.25%. Pennant Group's return on equity of 13.06% beat Ensign Group's return on equity of 15.07%.

Pennant Group has a consensus price target of $38.25, signalling upside risk potential of 40.17%. On the other hand Ensign Group has an analysts' consensus of $169.50 which suggests that it could grow by 27.93%. Given that Pennant Group has higher upside potential than Ensign Group, analysts believe Pennant Group is more attractive than Ensign Group.

Pennant Group has a beta of 1.935, which suggesting that the stock is 93.465% more volatile than S&P 500. In comparison Ensign Group has a beta of 0.935, suggesting its less volatile than the S&P 500 by 6.508%.

Pennant Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ensign Group offers a yield of 0.18% to investors and pays a quarterly dividend of $0.06 per share. Pennant Group pays -- of its earnings as a dividend. Ensign Group pays out 6.16% of its earnings as a dividend. Ensign Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pennant Group quarterly revenues are $180.7M, which are smaller than Ensign Group quarterly revenues of $1.1B. Pennant Group's net income of $6.2M is lower than Ensign Group's net income of $78.4M. Notably, Pennant Group's price-to-earnings ratio is 39.03x while Ensign Group's PE ratio is 32.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pennant Group is 1.25x versus 1.87x for Ensign Group. Usually stocks with elevated PS ratios are considered overvalued.

Guardian Pharmacy Services has a net margin of 3.43% compared to Pennant Group's net margin of -38.8%. Pennant Group's return on equity of 13.06% beat Guardian Pharmacy Services's return on equity of -109.2%.

Pennant Group has a consensus price target of $38.25, signalling upside risk potential of 40.17%. On the other hand Guardian Pharmacy Services has an analysts' consensus of -- which suggests that it could grow by 21.27%. Given that Pennant Group has higher upside potential than Guardian Pharmacy Services, analysts believe Pennant Group is more attractive than Guardian Pharmacy Services.

Pennant Group has a beta of 1.935, which suggesting that the stock is 93.465% more volatile than S&P 500. In comparison Guardian Pharmacy Services has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pennant Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardian Pharmacy Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pennant Group pays -- of its earnings as a dividend. Guardian Pharmacy Services pays out 160.75% of its earnings as a dividend.

Pennant Group quarterly revenues are $180.7M, which are smaller than Guardian Pharmacy Services quarterly revenues of $314.4M. Pennant Group's net income of $6.2M is higher than Guardian Pharmacy Services's net income of -$122M. Notably, Pennant Group's price-to-earnings ratio is 39.03x while Guardian Pharmacy Services's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pennant Group is 1.25x versus 1.04x for Guardian Pharmacy Services. Usually stocks with elevated PS ratios are considered overvalued.

LifeStance Health Group has a net margin of 3.43% compared to Pennant Group's net margin of -1.91%. Pennant Group's return on equity of 13.06% beat LifeStance Health Group's return on equity of -6.64%.

Pennant Group has a consensus price target of $38.25, signalling upside risk potential of 40.17%. On the other hand LifeStance Health Group has an analysts' consensus of $8.70 which suggests that it could grow by 10.97%. Given that Pennant Group has higher upside potential than LifeStance Health Group, analysts believe Pennant Group is more attractive than LifeStance Health Group.

Pennant Group has a beta of 1.935, which suggesting that the stock is 93.465% more volatile than S&P 500. In comparison LifeStance Health Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pennant Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeStance Health Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pennant Group pays -- of its earnings as a dividend. LifeStance Health Group pays out -- of its earnings as a dividend.

Pennant Group quarterly revenues are $180.7M, which are smaller than LifeStance Health Group quarterly revenues of $312.7M. Pennant Group's net income of $6.2M is higher than LifeStance Health Group's net income of -$6M. Notably, Pennant Group's price-to-earnings ratio is 39.03x while LifeStance Health Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pennant Group is 1.25x versus 2.45x for LifeStance Health Group. Usually stocks with elevated PS ratios are considered overvalued.

PACS Group has a net margin of 3.43% compared to Pennant Group's net margin of -1.11%. Pennant Group's return on equity of 13.06% beat PACS Group's return on equity of --.

Pennant Group has a consensus price target of $38.25, signalling upside risk potential of 40.17%. On the other hand PACS Group has an analysts' consensus of $34.83 which suggests that it could grow by 160.92%. Given that PACS Group has higher upside potential than Pennant Group, analysts believe PACS Group is more attractive than Pennant Group.

Pennant Group has a beta of 1.935, which suggesting that the stock is 93.465% more volatile than S&P 500. In comparison PACS Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pennant Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PACS Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pennant Group pays -- of its earnings as a dividend. PACS Group pays out 71.23% of its earnings as a dividend. PACS Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pennant Group quarterly revenues are $180.7M, which are smaller than PACS Group quarterly revenues of $981.8M. Pennant Group's net income of $6.2M is higher than PACS Group's net income of -$10.9M. Notably, Pennant Group's price-to-earnings ratio is 39.03x while PACS Group's PE ratio is 20.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pennant Group is 1.25x versus 0.59x for PACS Group. Usually stocks with elevated PS ratios are considered overvalued.